Seeking women at least 18 years of age with confirmed or recurrent endometrial cancer for study of an investigational drug
We are studying the effect of a investigational drug called Pembrolizumab compared to Platinum Doublet Chemotherapy in patients with recurrent endometrial cancer.
What we're hoping for
Evaluate the safety, tolerablity, and how well Pembrolizumab works compared to Platinum Doublet Chemotherapy.
ClinicalTrials.gov Identifier: NCT05173987